ENISOPROST

Details

Stereochemistry	MIXED
Molecular Formula	C22H36O5
Molecular Weight	380.5182
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 4
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]1(CC\C=C/CCC(=O)OC)C(=O)C[C@@H](O)[C@]1([H])\C=C\CC(C)(O)CCCC

InChI

InChIKey=CIBHDGPIOICRGX-ZQCHCGQNSA-N

InChI=1S/C22H36O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h6-7,10,12,17-18,20,24,26H,4-5,8-9,11,13-16H2,1-3H3/b7-6-,12-10+/t17-,18-,20-,22?/m1/s1

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800000607 | https://www.ncbi.nlm.nih.gov/pubmed/1750068 | https://www.ncbi.nlm.nih.gov/pubmed/2979675

Enisoprost is a prostaglandin E1 analog. Enisoprost exerts immunosuppressive activity and gastric antisecretory effect. Enisoprost was being studied for the treatment of peptic ulcer and transplant rejection. Enisoprost development has been discontinued.

Originator

Approval Year

Sample Use Guides

In Vitro Use Guide

Effective suppression of IL-4 production in stimulated murine splenic T cells was seen for enisoprost with KI(50) of 20 nM

Name

Type

Language

ENISOPROST

Official Name

English

ENISOPROST [MART.]

Common Name

English

SC-34301

Code

English

ENISOPROST [USAN]

Common Name

English

enisoprost [INN]

Common Name

English

(±)-METHYL (Z)-7-((1R,2R,3R)-3-HYDROXY-2-((E)-(4RS)-4-HYDROXY-4-METHYL-1-OCTENYL)-5-OXOCYCLOPENTYL)-4-HEPTENOATE

Systematic Name

English

PROSTA-4,13-DIEN-1-OIC ACID, 11,16-DIHYDROXY-16-METHYL-9-OXO-, METHYL ESTER, (4Z,11.ALPHA.,13E)-(±)-

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

37289